• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

1.82 EUR

+3.76 %

2,210 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+3.76 %
-17.27 %
+1.68 %
-26.91 %
-19.11 %
-43.65 %
-51.72 %
-
-64.03 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
61.49M EUR
Turnover
45.02K EUR
P/E (adj.) (26e)
-7.35
EV/EBIT (adj.) (26e)
-7.59
P/B (26e)
4.54
EV/S (26e)
13.57
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Here are Antti’s comments regarding this recent pleasant news. Aiforia announced on Thursday that it has been selected as the provider of AI-assisted diagnostic solutions for a Spanish regional healthcare provider. The agreement covers nine hospitals, which will be supplied with ...
19 hours ago
by Sijoittaja-alokas
30
Well, something is finally happening amidst the silence. Aiforialle uusi kliininen asiakkuus Espanjassa
yesterday
by Vekas
27
LinkedIn Development of convolutional neural networks for automated brain-wide... Speeding up image analysis time from weeks to minutes. ⏱️ That's how AI is transforming preclinical synucleinopathy research. Traditional characterization of histological samples in neurodegenerative...
5/22/2026, 7:58 AM
by Salvelinus
15
Grundium, a company emerging from the camera and computer vision hub in Hervanta, has acquired Aiforia’s competitor, Visiopharm. It seems that firms providing these machine learning models and software are now in high demand. Grundium – 21 May 26 Grundium Acquires Visiopharm to Create...
5/21/2026, 3:09 PM
by Loiskuttaja
15
As far as I know, this is so new that there haven’t been any American or European players in this space before. If I remember correctly, they have won every competitive tender, which must say something. I don’t know if it’s a moat, but it’s at least some kind of qualitative head ...
yesterday
by ooskari
14
Has anyone done an analysis yet on how significant of a moat and competitive advantage Aiforia’s European origin is in the European market, given the desire to reduce dependence on American IT systems? It would be quite a situation if “made in Europe” allows Aiforia to conquer the...
yesterday
12
https://www.pathologynews.com/first-all-in-one-digital-pathology-tool-techcytes-fusion-platform-to-improve-pathologists-workflow-and-integrate-ai/ There’s a link with some buzz regarding Aiforia’s collaboration setups. It has been quiet regarding Aiforia for a long time—either frighteningl...
yesterday
by Salvelinus
10
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8
2026

Interim report Q2'26

Aiforia expands to nine hospitals in Spain
Analyst Comment19 hours ago by
Antti Siltanen

Aiforia expands to nine hospitals in Spain

The news continues Aiforia's series of gradual growth steps with 9 new hospitals.

Aiforia Technologies
Press releaseyesterday

Aiforia expands its presence in Spain through a new clinical account

Aiforia Technologies
Regulatory press release5/18/2026, 2:00 PM

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act - Mikko Laakkonen’s holding in Aiforia Technologies Plc

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
M&A activity in digital pathology is increasing
Analyst Comment5/15/2026, 6:45 AM by
Antti Siltanen, Antti Luiro

M&A activity in digital pathology is increasing

Consolidation has occurred in Aiforia's industry over the past 12–18 months.

Aiforia Technologies
Regulatory press release5/12/2026, 10:00 AM

Resolutions of Aiforia Technologies Plc’s Extraordinary General Meeting 2026

Aiforia Technologies
Third party research5/11/2026, 7:18 AM

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)

(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection...

Aiforia Technologies
Third party research5/11/2026, 6:12 AM

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research

Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal...

Aiforia Technologies
Aiforia's AI solutions expand at Fimlab
Analyst Comment4/28/2026, 6:17 AM by
Antti Siltanen

Aiforia's AI solutions expand at Fimlab

Fimlab is expanding the use of AI diagnostics to several new cancer types and increasing the number of samples analyzed.

Aiforia Technologies
Press release4/27/2026, 6:00 AM

Fimlab expands utilization of Aiforia's clinical AI solutions

Aiforia Technologies
Regulatory press release4/24/2026, 8:00 AM

Aiforia Technologies Plc: Share subscriptions based on stock options 2016A

Aiforia Technologies
Aiforia signs agreement with Italian laboratory
Analyst Comment4/24/2026, 6:58 AM by
Antti Siltanen

Aiforia signs agreement with Italian laboratory

The new agreement initially brings AI to cervical cancer diagnostics.

Aiforia Technologies
Press release4/23/2026, 8:00 AM

Aiforia closes a deal with a private diagnostic laboratory in Italy

Aiforia Technologies
Life Science Night | November 30, 2026
Webcast11/30/2026, 2:00 PM by
Antti Siltanen

Life Science Night | November 30, 2026

Welcome to follow Life Science Night on Monday, November 30 at 4:00 pm EET on inderesTV.

Aiforia Technologies
Regulatory press release4/17/2026, 3:45 PM

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Third party research4/17/2026, 6:14 AM

Aiforia secures landmark hospital group as sole AI provider - NuWays AG Research

Aiforia France has been selected as the sole AI partner for the French government-backed PROSTIA project. The partnership expands Aiforia's existing Assistance Publique-Hôpitaux de Paris (AP-HP) relationship from 2 to 7 hospitals, integrating its prostate...

Aiforia Technologies
Aiforia to five new hospitals in France
Analyst Comment4/17/2026, 5:59 AM by
Antti Siltanen

Aiforia to five new hospitals in France

The two-year project lays the groundwork for the use of Aiforia's solutions in the longer term.

Aiforia Technologies
Regulatory press release4/16/2026, 2:00 PM

Aiforia Technologies Plc: Resolutions of the constitutive meeting of the Board of Directors

Aiforia Technologies
Press release4/16/2026, 9:00 AM

Aiforia has been selected as an AI partner for the PROSTIA project - expands to five new hospitals in Paris

Aiforia Technologies
Regulatory press release4/15/2026, 6:00 AM

Notice of Aiforia Technologies Plc’s Extraordinary General Meeting 2026

Aiforia Technologies
Regulatory press release4/8/2026, 12:15 PM

Aiforia Technologies Plc – Managers’ Transactions – Antti Ojala

Aiforia Technologies